A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an efficacious dose of QAT370 compared to open-label tiotropium bromide following once daily dosing for 7 days in COPD [chronic obstructive pulmonary disease] patients

Trial Profile

A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an efficacious dose of QAT370 compared to open-label tiotropium bromide following once daily dosing for 7 days in COPD [chronic obstructive pulmonary disease] patients

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2010

At a glance

  • Drugs QAT 370; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 20 Jan 2008 Status changed from recruiting to completed.
    • 02 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top